A retrospective cohort study evaluated the association between rivaroxaban and clinical outcomes in patients with AMI and preexisting AF, though specific results were not reported in the abstract.
Cohort
Does rivaroxaban improve clinical outcomes in patients with acute myocardial infarction and preexisting atrial fibrillation?
Atrial fibrillation (AF), the most common arrhythmia, is correlated with elevated risk of myocardial infarction. Patients presenting with acute myocardial infarction (AMI) who have preexisting AF demonstrate higher rates of adverse events than those with new-onset AF 1. However, in clinical practice, some patients exhibit suboptimal adherence and do not consistently receive anticoagulant therapy. Limited data are available regarding direct oral anticoagulant (DOAC) use among patients with AMI and preexisting AF, particularly in Asian populations. Recent real-world studies have demonstrated that rivaroxaban is the most frequently prescribed DOAC in China 2. Therefore, we conducted a retrospective cohort study using the database from the Tianjin Health and Medical Big Data Super Platform to explore the association between rivaroxaban and clinical outcomes in patients with AMI and preexisting AF (Figure 1).
Liu et al. (Wed,) conducted a cohort in Acute myocardial infarction and preexisting atrial fibrillation. Rivaroxaban was evaluated on Clinical outcomes. A retrospective cohort study evaluated the association between rivaroxaban and clinical outcomes in patients with AMI and preexisting AF, though specific results were not reported in the abstract.